Here are four observations:
1. In 2015, the market was valued at $160 million.
2. The market is expected to be worth $451.9 million by 2024.
3. The pure-platelet rich plasma segment accounted for more than 60 percent of the market.
4. Key market players include:
• AdiStem in Australia
• Arthrex in Naples, Fla.
• Zimmer Biomet in Warsaw, Ind.
• Cesca Therapeutics in Rancho Cordova, Calif.
• DePuy Synthes in West Chester, Pa.
• EmCyte Corp. in Fort Myers, Fla.
• Exactech in Gainesville, Fla.
• Harvest Technologies Corp. in Plymouth, Mass.
• Nuo Therapeutics in Gaithersburg, Md.
• Regen Lab in Le Mont-sur-Lausanne, Switzerland
• Stryker Corp. in Kalamazoo, Mich.
More articles on spine:
Dr. Patrick Senatus induced into International Association of HealthCare Professionals: 5 things to know
SCS therapy declines or stabilizes opioid usage: 4 insights
5 things to know about gunshot-induced spinal cord injury: Is surgery overused?
